SEC Form EFFECT filed by Silexion Therapeutics Corp
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | September 30, 2025 5:00 P.M. |
Form: | S-3 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | September 30, 2025 5:00 P.M. |
Form: | S-3 | ||||||
|
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence of gastric cancer activity expands potential therapeutic reach of SIL204 GRAND CAYMAN, Cayman Islands, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that SIL204 has demonstrated activity against eleven human cell lines originating from 5 different organ cancer sites, each with a specific KRAS mutation. Hi
GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), concerning the minimum bid price and shareholders' equity requirements. The letter, dated September 23, 2025, confirmed that the Company has successfully met the minimum bid price requirement of $1.00 per share. Additionally, Nasdaq conf
Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 1,500,000 of the Company's ordinary shares (or ordinary share equivalents), series A warrants to purchase up to 1,500,000 ordinary shares and series B warrants to purchase up to 1,500,000 ordinary shares at a combined public offering price of $4.00 per share (or per ordinary share equivalent) and accompanying warrants. The series A warrants will have an exercise price of $4.00 per share, will be
EFFECT - Silexion Therapeutics Corp (0002022416) (Filer)
8-K - Silexion Therapeutics Corp (0002022416) (Filer)
S-3 - Silexion Therapeutics Corp (0002022416) (Filer)
3 - Silexion Therapeutics Corp (0002022416) (Issuer)
Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-15 reverse share split of its ordinary shares. The reverse share split will become effective after market close on July 28, 2025, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on July 29, 2025, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 27, 2024, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Global Market at market open on November 29, 2024, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every nine ordinary shares of
Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov
SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)
SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)
SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)